Associations between clinical variables and treatment regimens and hair density and caliber in female androgenetic alopecia patients: A retrospective study of 602 patients

2021 ◽  
Author(s):  
H Tuan ◽  
L Yin ◽  
K Lo Sicco ◽  
J Shapiro
Keyword(s):  
Retrospective Study ◽  
Androgenetic Alopecia ◽  
Hair Density ◽  
Clinical Variables ◽  
Treatment Regimens

Comparison of efficacy of topical 5% minoxidil alone versus topical 5% minoxidil with autologous Platelet Rich Plasma (PRP) therapy in treatment of androgenetic alopecia: A randomised open label study

2021 ◽  
Vol 7 (2) ◽  
pp. 107-114
Author(s):  
Bela Padhiar ◽  
Sruthy Raveendran
Keyword(s):  
Platelet Rich Plasma ◽  
Androgenetic Alopecia ◽  
Androgenic Alopecia ◽  
Open Label ◽  
Hair Density ◽  
Convenience Sample ◽  
Double Spin ◽  
Autologous Platelet Rich Plasma ◽  
Group B ◽  
Autologous Platelet

Androgenic alopecia (AGA) is a type of progressive hairloss, where there is androgen mediated conversion of susceptible terminal hairs into vellus hairs, in genetically predisposed individuals. To compare efficacy of Topical 5% Minoxidil alone versus Topical 5% Minoxidil with Autologous Platelet Rich Plasma (PRP) therapy in patients with Androgenetic Alopecia.This is aProspective study conducted in Department of Dermatology GMERS Medical College, Gandhinagar, Gujarat. A convenience sample of 62 men in the age group of 20-40 with Grade 2-5 AGA according to Hamilton- Norwood Grading were selected and was divided into 2 groups of 31 each. Presitting digital photographs and dermoscopic photos were taken. Autologous PRP was prepared using 18 ml of patients blood after double spin centrifugation and injected by Nappage technique. Results were assessed at the baseline and at the end of each sitting on the basis of change in hair density, photographic evaluation and patient’s self satisfaction. Highly significant increase in hair density was achieved after 4 months of treatment. At T4 (Fourth Session of treatment) Group B showed higher hair density (42.97± 8.96) as compared to Group A (36.94 ± 11.57) which was statistically significant at P = 0.03Group B showed better improvement as compared to Group A.PRP treatment has a positive therapeutic effect on male Androgenetic alopecia without major side effects.

scholarly journals Hair Growth Promotion by Extracts of Inula Helenium and Caesalpinia Sappan Bark in Patients with Androgenetic Alopecia: A Pre-clinical Study Using Phototrichogram Analysis

Cosmetics ◽  
2019 ◽  
Vol 6 (4) ◽  
pp. 66
Author(s):  
Hyoung Chul Choi ◽  
Gae Won Nam ◽  
Noh Hee Jeong ◽  
Bu Young Choi
Keyword(s):  
Clinical Study ◽  
Hair Loss ◽  
Hair Growth ◽  
Blood Circulation ◽  
Growth Promotion ◽  
Test Group ◽  
Androgenetic Alopecia ◽  
Hair Density ◽  
Caesalpinia Sappan ◽  
Inula Helenium

Inula helenium (IH) is known to possess antifungal, anti-bacterial, anti-helminthic, and anti-proliferation activities. Caesalpinia Sappan (CS) is known to reduce inflammation and improve blood circulation. Based on their folkloric use, these plants are expected to be promising candidates for promoting hair growth and preventing hair loss. Moreover, these plants are rich sources of certain phytochemicals, which have been reported to promote hair growth. In this clinical trial, we investigate the efficacy of a scalp shampoo formulated by mixing extracts of IH and CS in preventing hair loss and promoting hair growth in patients with androgenetic alopecia. Using a phototrichogram (Folliscope 2.8, LeadM, Korea), we compared the hair density and total hair counts in patients receiving the scalp shampoo at baseline, and at 8, 16, and 24 weeks after use of the shampoo. We found a statistically significant increase in the total hair count in the test group (n = 23) after 16 and 24 weeks of using the scalp shampoo (2.17 n/cm2 ± 5.72, p < 0.05; and 4.30 n/cm2 ± 6.37, p < 0.01, respectively) as compared to the control subjects. Based on the results of this clinical study, we conclude that the IH and CS extract complex is a promising remedy for preventing hair loss and promoting hair growth.

Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study

2003 ◽  
Vol 60 (1) ◽  
pp. 47-55 ◽  
Author(s):  
A.C. Altamura ◽  
R. Bassetti ◽  
S. Bignotti ◽  
R. Pioli ◽  
E. Mundo
Keyword(s):  
Retrospective Study ◽  
Suicide Attempts ◽  
Clinical Variables ◽  
Schizophrenic Patients

Myalgia in Patients with Dermatomyositis and Polymyositis Is Attributable to Fasciitis Rather Than Myositis: A Retrospective Study of 32 Patients who Underwent Histopathological Examinations

2017 ◽  
Vol 44 (4) ◽  
pp. 482-487 ◽  
Author(s):  
Kentaro Noda ◽  
Ken Yoshida ◽  
Taro Ukichi ◽  
Kazuhiro Furuya ◽  
Kenichiro Hirai ◽  
...  
Keyword(s):  
Creatine Kinase ◽  
Retrospective Study ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Medical Records ◽  
Histopathological Examination ◽  
Newly Diagnosed ◽  
Manual Muscle Test ◽  
Clinical Variables ◽  
The Relationship

Objective.To determine the association between fasciitis and the clinical variables in patients with dermatomyositis (DM) and polymyositis (PM).Methods.We retrospectively reviewed the medical records of 32 patients (24 DM, 8 PM) with newly diagnosed DM and PM and in whom fascia and muscle specimens were histopathologically examined. The relationship between fasciitis and the clinical variables was statistically analyzed. These included age, sex, myalgia, muscle weakness, creatine kinase (CK) and aldolase activities, anti-Jo1 antibody, interstitial lung disease, and malignancy.Results.Twenty (62.5%) of the 32 patients who underwent the histopathological examination of a fascia specimen had fasciitis, including 18 (75%) of 24 patients with DM and 2 (25%) of 8 patients with PM. The frequency of fasciitis was significantly higher among the patients with DM than among the patients with PM (p < 0.05). Histopathologically, fasciitis in PM was very mild in comparison to that in DM. The frequency of myalgia in patients with fasciitis was significantly higher than that in patients without fasciitis (p < 0.05). However, myalgia was not associated with myositis. There were no significant differences in the patients with and without fasciitis in age, sex, manual muscle test 8 scores, CK or aldolase activities, or the presence of anti-Jo1 antibodies and malignancy.Conclusion.The frequency of fasciitis was significantly higher among patients with DM than among those with PM. Fasciitis, rather than myositis, was associated with myalgia.

scholarly journals Optimization of systemic juvenile arthritis treatment regimens with correction of tocilizumab intravenous administration according to data of observational retrospective study

2019 ◽  
Vol 57 (2) ◽  
pp. 229-234
Author(s):  
M. I. Kaleda ◽  
I. P. Nikishina ◽  
O. M. Kostareva
Keyword(s):  
Retrospective Study ◽  
Age Of Onset ◽  
Ferritin Level ◽  
Juvenile Arthritis ◽  
Active Growth ◽  
Initial Interval ◽  
Treatment Regimens ◽  
Reactive Protein ◽  
Group 2 ◽  
Group 1

Objective: to assess the possibility of using varying interval between intravenous infusions of tocilizumab (TCZ) as a tool for choosing the optimal treatment regimen in systemic juvenile arthritis (SJA).Subjects and methods. The observational retrospective study included 72 patients (29 boys and 43 girls) with a SJA fulfilled ILAR criteria, who received TCZ ≥12 months, in which previous therapy with various anti-rheumatic drugs was ineffective. We studied the changes of the main clinical and laboratory parameters of the SJA activity after correction of the interval between infusions.Results and discussion. In the studied group median age of onset was 3.8 [2.1; 5.9] years, duration of disease before the appointment of TCZ – 26.5 [9.25; 62.25] months. Therapy is continued by 70 patients, the median duration of therapy is 5.0 [2.75; 6.38] years. The initial interval between TCZ infusions was 2 weeks in 49 (group 1) and 4 weeks in 23 patients (group 2). After 6 months of therapy in group 2, the interval was reduced to 2 weeks in 15 (65.2%) patients due to decreased effectiveness. Prolongation of the period between the introduction of TCZ in patients of group 1 who did not reach the inactive status of the disease in the 1st year of the disease resulted in a significant increase of erythrocyte sedimentation rate, C-reactive protein level and exacerbation of systemic manifestations of SJA (p<0.01) in the absence of statistically significant changes of joint status parameters (p>0.05). 40% of these patients had involvement of «new» joints, including hip joints. «Harbingers» of exacerbation in the period of increasing intervals between infusions were: arthralgia (88%), myalgia (65%), sore throat (30%), dysphoria (50%, more often in preschool children), increase of ferritin level and number of leukocytes. In 90.3% of patients who have reached the inactive status of the disease, it was possible to gradually increase the interval between infusions. In 6 patients, TCZ was canceled by gradually increasing the intervals, in 4 of them, therapy was resumed at an initial interval of 2 weeks after 3, 6, 21 and 22 months, respectively, in two patients, a drug-free remission was maintained during 23 and 20 months. Reduction of intervals to the initial 2 weeks was performed in 13 (18.1%) patients. The development of exacerbations with the need to reduce the interval to the initial one was most often observed at 24–35 months of therapy, which chronologically coincided with the period of active growth. Currently, 15 patients receiving TCZ with an interval of 5–6 weeks, and 40 – with an interval of 4 weeks, 9 patients – 3 weeks, in 6 patients attempt to increase the interval to more than 2–2,5 weeks was unsuccessful.Conclusion. Experience suggests the need to comply with a two-week interval between infusions of TCZ at the initial stage of therapy in most patients with SJA until the inactive stage of the disease, followed by a smooth individual increase in the interval to 4 weeks (2–3 days under careful medical supervision). Appearance of initial signs of exacerbation, requires to reduce the interval to 2 weeks. Before deciding on the complete withdrawal of TCZ, it is advisable to increase the interval between infusions to 5–6 weeks under careful clinical and laboratory control.

Sign in / Sign up

Export Citation Format

Share Document